Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMX160 is a standardized botanical extract derived from the fresh fruit of Indian Gooseberry (*Phyllanthus emblica* L., also known as *Emblica officinalis*). Developed by Arjuna Natural, it is primarily investigated for the management of hypercholesterolemia and dyslipidemia. The extract is characterized by a high concentration of bioactive polyphenols and flavonoids. Its mechanism of action involves the inhibition of hepatic 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol biosynthesis, which leads to a reduction in total cholesterol, LDL cholesterol, and triglycerides. Additionally, AMX160 exhibits potent antioxidant properties that help attenuate lipid peroxidation. It is marketed under the brand name Tri-low as a nutraceutical ingredient for cardiovascular health and has been evaluated in clinical trials as a natural alternative or adjunct to conventional lipid-lowering therapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AMX160.